GB2522615A - Assay and medicament - Google Patents

Assay and medicament Download PDF

Info

Publication number
GB2522615A
GB2522615A GB1400752.0A GB201400752A GB2522615A GB 2522615 A GB2522615 A GB 2522615A GB 201400752 A GB201400752 A GB 201400752A GB 2522615 A GB2522615 A GB 2522615A
Authority
GB
United Kingdom
Prior art keywords
rna
virus
segment
influenza
segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1400752.0A
Other languages
English (en)
Other versions
GB201400752D0 (en
Inventor
Nigel J Dimmock
Andrew J Easton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Priority to GB1400752.0A priority Critical patent/GB2522615A/en
Publication of GB201400752D0 publication Critical patent/GB201400752D0/en
Priority to EP22162159.2A priority patent/EP4085917A1/en
Priority to DK15701244.4T priority patent/DK3094338T3/da
Priority to PL15701244.4T priority patent/PL3094338T3/pl
Priority to JP2016546969A priority patent/JP6781045B2/ja
Priority to US15/111,615 priority patent/US20160333321A1/en
Priority to EP15701244.4A priority patent/EP3094338B1/en
Priority to ES15701244T priority patent/ES2913063T3/es
Priority to PCT/GB2015/050094 priority patent/WO2015107357A1/en
Publication of GB2522615A publication Critical patent/GB2522615A/en
Priority to US16/230,114 priority patent/US11339374B2/en
Priority to US17/725,982 priority patent/US20220325251A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB1400752.0A 2014-01-16 2014-01-16 Assay and medicament Withdrawn GB2522615A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB1400752.0A GB2522615A (en) 2014-01-16 2014-01-16 Assay and medicament
PCT/GB2015/050094 WO2015107357A1 (en) 2014-01-16 2015-01-16 Assay and medicament
JP2016546969A JP6781045B2 (ja) 2014-01-16 2015-01-16 アッセイ及び薬剤
DK15701244.4T DK3094338T3 (da) 2014-01-16 2015-01-16 Test og lægemiddel
PL15701244.4T PL3094338T3 (pl) 2014-01-16 2015-01-16 Oznaczenie i lek
EP22162159.2A EP4085917A1 (en) 2014-01-16 2015-01-16 Assay and medicament
US15/111,615 US20160333321A1 (en) 2014-01-16 2015-01-16 Assay and medicament
EP15701244.4A EP3094338B1 (en) 2014-01-16 2015-01-16 Assay and medicament
ES15701244T ES2913063T3 (es) 2014-01-16 2015-01-16 Ensayo y medicamento
US16/230,114 US11339374B2 (en) 2014-01-16 2018-12-21 Assay and medicament
US17/725,982 US20220325251A1 (en) 2014-01-16 2022-04-21 Assay and medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1400752.0A GB2522615A (en) 2014-01-16 2014-01-16 Assay and medicament

Publications (2)

Publication Number Publication Date
GB201400752D0 GB201400752D0 (en) 2014-03-05
GB2522615A true GB2522615A (en) 2015-08-05

Family

ID=50239057

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1400752.0A Withdrawn GB2522615A (en) 2014-01-16 2014-01-16 Assay and medicament

Country Status (8)

Country Link
US (3) US20160333321A1 (enExample)
EP (2) EP4085917A1 (enExample)
JP (1) JP6781045B2 (enExample)
DK (1) DK3094338T3 (enExample)
ES (1) ES2913063T3 (enExample)
GB (1) GB2522615A (enExample)
PL (1) PL3094338T3 (enExample)
WO (1) WO2015107357A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046689A1 (en) * 2021-02-18 2022-08-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza virus defective interfering particles for use in the prophylactic or therapeutic treatment of coronaviridae infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2437799A (en) * 2006-05-24 2007-11-07 Univ Warwick Defective interfering (DI) virus
WO2007135420A2 (en) * 2006-05-24 2007-11-29 The University Of Warwick Defective interfering virus
WO2010067109A1 (en) * 2008-12-12 2010-06-17 The University Of Warwick Anti-viral protection with viruses containing defective genome segments
US20130156733A1 (en) * 2011-12-20 2013-06-20 Philip I. Marcus Influenza virus populations, methods of use and methods of making thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408424D0 (en) * 2004-04-15 2004-05-19 Univ Warwick Viral assay
EP2272950A3 (en) * 2004-11-11 2011-07-20 Abbott Biologicals B.V. Defective influenza virus particles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2437799A (en) * 2006-05-24 2007-11-07 Univ Warwick Defective interfering (DI) virus
WO2007135420A2 (en) * 2006-05-24 2007-11-29 The University Of Warwick Defective interfering virus
WO2010067109A1 (en) * 2008-12-12 2010-06-17 The University Of Warwick Anti-viral protection with viruses containing defective genome segments
US20130156733A1 (en) * 2011-12-20 2013-06-20 Philip I. Marcus Influenza virus populations, methods of use and methods of making thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antiviral Research, Vol. 96, No. 3, Dec. 2012, N Dimmock, et al., "Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.", pages 376 - 385. *
Journal of Virology, Vol. 82, No. 17, Sept. 2008, N Dimmock, et al., "Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral", pages 8570 - 8578. *
Reviews in Medical Virology, Vol. 20, No. 1, Jan. 2010, AC Marriott , et al., "Defective interfering viruses and their potential as antiviral agents", pages 51 - 62. *

Also Published As

Publication number Publication date
JP2017504331A (ja) 2017-02-09
US11339374B2 (en) 2022-05-24
US20220325251A1 (en) 2022-10-13
DK3094338T3 (da) 2022-05-23
WO2015107357A1 (en) 2015-07-23
EP4085917A1 (en) 2022-11-09
JP6781045B2 (ja) 2020-11-04
PL3094338T3 (pl) 2022-08-08
EP3094338B1 (en) 2022-04-13
GB201400752D0 (en) 2014-03-05
US20160333321A1 (en) 2016-11-17
EP3094338A1 (en) 2016-11-23
US20200231939A1 (en) 2020-07-23
ES2913063T3 (es) 2022-05-31

Similar Documents

Publication Publication Date Title
Naffakh et al. Host restriction of avian influenza viruses at the level of the ribonucleoproteins
Vasin et al. Molecular mechanisms enhancing the proteome of influenza A viruses: an overview of recently discovered proteins
Powell et al. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity
US20220241396A1 (en) Mutations that confer genetic stability to genes in influenza viruses
Wolff et al. Influenza B, C and D viruses (orthomyxoviridae)
EP2747778B1 (en) Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
Luo et al. Characterization of a hemagglutinin-specific inhibitor of influenza A virus
AU2017221444A1 (en) Improved influenza B virus replication for vaccine development
Meng et al. Unexpected complexity in the interference activity of a cloned influenza defective interfering RNA
CA2918739C (en) Attenuated influenza vaccines and uses thereof
JP2017529084A (ja) ピチンデウイルスのリバースジェネティクス系及び使用方法
US20220325251A1 (en) Assay and medicament
Abbas et al. Proteins of Influenza Virus: A Review
Muraki et al. Palmitoylation of CM2 is dispensable to influenza C virus replication
US9499595B2 (en) Development of influenza A antivirals
AbuBakar et al. Avian Influenza Virus Tropism in Humans. Viruses. 2023; 15: 833
Winn The role of host factor Transportins in Influenza virus entry and infection
Xiao Influenza A virus interferes with innate immune signaling in avian cells
Feder Internal viral RNA sequences of the PB2 genome segment of influenza A virus are required for efficient generation of fully infectious particles
Pizzorno Mechanisms of resistance to neuraminidase inhibitors in influenza A viruses and evaluation of combined antiviral therapy
KR102061658B1 (ko) 뉴라미니다제 억제제에 대해 저항성을 나타내는 인플루엔자 바이러스의 스크리닝 방법
Turnbull The Role of the NS Segment of Influenza A Virus in Setting Host Range and Pathogenicity
Abbas Special Issues
Keane Investigation of host factors in influenza a virus infection
Sanchez Influenza nucleoprotein interactions as potential antiviral targets

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)